BA
AXSM icon

Bridgewater Associates’s Axsome Therapeutics AXSM Stock Holding History

Bridgewater Associates’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.2M Buy
58,217
+1,266
+2% +$275K 0.06% 267
2026
Q1 		$9.63M Buy
56,951
+9,507
+20% +$1.64M 0.04% 273
2025
Q4 		$8.67M Buy
+47,444
New +$6.62M 0.03% 392
2025
Q3 		– Sell
-107,292
Closed -$11.2M – 1019
2025
Q2 		$11.2M Buy
107,292
+64,467
+151% +$6.83M 0.05% 240
2025
Q1 		$4.99M Buy
+42,825
New +$4.88M 0.02% 356

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bridgewater Associates's AXSM Position: Q2 2026 in Review

Bridgewater Associates increased its Axsome Therapeutics (AXSM) stake by 2.2% in Q2 2026, buying an estimated $275K and bringing the position to 58,217 shares worth $14.2M. The position accounts for 0.06% of the portfolio, ranked #267.

Bridgewater Associates first reported a position in AXSM in Q1 2025 and has held it in 5 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Bridgewater Associates held 58,217 shares of Axsome Therapeutics worth $14.2M as of Q2 2026.
  • Bridgewater Associates bought 1,266 Axsome Therapeutics shares in Q2 2026, an estimated $275K.
  • Axsome Therapeutics made up 0.06% of Bridgewater Associates's portfolio in Q2 2026, its #267 holding.
  • Bridgewater Associates first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.